Shares of Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) have been given an average recommendation of “Buy” by the seven research firms that are currently covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $15.40.
A number of research analysts recently commented on FOMX shares. Cowen set a $30.00 price target on Foamix Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, September 23rd. Zacks Investment Research upgraded shares of Foamix Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, October 22nd. Finally, HC Wainwright reissued a “buy” rating and issued a $11.00 target price (up from $10.00) on shares of Foamix Pharmaceuticals in a report on Monday, October 21st.
NASDAQ:FOMX traded down $0.10 during trading hours on Tuesday, reaching $2.87. 51,068 shares of the company were exchanged, compared to its average volume of 1,250,947. The business has a 50 day moving average of $3.33 and a 200 day moving average of $2.89. Foamix Pharmaceuticals has a 1-year low of $1.97 and a 1-year high of $4.48. The company has a debt-to-equity ratio of 0.24, a current ratio of 5.72 and a quick ratio of 5.72. The company has a market capitalization of $181.61 million, a P/E ratio of -1.69 and a beta of 1.53.
Institutional investors and hedge funds have recently modified their holdings of the company. Royal Bank of Canada lifted its position in shares of Foamix Pharmaceuticals by 76.5% during the 2nd quarter. Royal Bank of Canada now owns 13,694 shares of the specialty pharmaceutical company’s stock worth $33,000 after buying an additional 5,937 shares during the last quarter. Stifel Financial Corp bought a new stake in shares of Foamix Pharmaceuticals during the 3rd quarter valued at approximately $54,000. grace capital increased its position in Foamix Pharmaceuticals by 86.9% during the 2nd quarter. grace capital now owns 20,000 shares of the specialty pharmaceutical company’s stock worth $48,000 after purchasing an additional 9,300 shares in the last quarter. Worth Venture Partners LLC increased its position in Foamix Pharmaceuticals by 75.0% during the 2nd quarter. Worth Venture Partners LLC now owns 23,627 shares of the specialty pharmaceutical company’s stock worth $56,000 after purchasing an additional 10,127 shares in the last quarter. Finally, Delek Group Ltd. lifted its stake in Foamix Pharmaceuticals by 23.2% in the 2nd quarter. Delek Group Ltd. now owns 62,437 shares of the specialty pharmaceutical company’s stock valued at $145,000 after purchasing an additional 11,741 shares during the last quarter. Institutional investors own 47.29% of the company’s stock.
Foamix Pharmaceuticals Company Profile
Foamix Pharmaceuticals Ltd., a late clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations for dermatological therapy in the United States, France, Denmark, and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline that has completed third pivotal Phase III clinical trial for the treatment of moderate-to-severe acne; and FMX103, which is in Phase III clinical trial for the treatment of moderate-to-severe papulopustular rosacea.
Further Reading: What are the qualifications of a portfolio manager?
Receive News & Ratings for Foamix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.